thanks. now can you explain how Elite's debt dropped $87 million in the last two years? there's been trash talk on this board about Elite being so deep in debt, but the balance sheet looks great, don't you think?
are you thinking about the 180-day exclusivity period given for the first generic that follows patent expiration for a branded drug
there is no exclusivity for a new drug, only patent protection as mjh has pointed out, so nobody can copy what Elite has done for some years
that's not to say there will not be competition in the abuse resistant immediate release oxy space, but nothing is imminent. so SequestOx will have an opportunity to gain acceptance with doctors and patients
how did you determine $12 million is adequate to launch SequestOx and maintain operations while waiting for first sales?
is that same $12 million going to be used to get the next two abuse resistant drugs to FDA or do you think Hakim should delay everything until Elite is self-funded?
do you realize that 63 million shares -- only 36 million of which are new -- represents just 7.9% of outstanding shares, and that this increase is deemed necessary at this time by the CEO who has brought the stock from .07 to over .30 in less than three years?
have you figured out yet how Elite reduced its debt by $87 million in the last two years?
Hakim might just be strengthening his bargaining position with Puracap (or others) by showing that he can get money from Lincoln to go it alone...
" And we can also decide whether we want to go at it our self. We’ll have to raise some money; we have some money but we’ll have to raise some money as well to do that."
there were only about 27 million shares left to sell Lincoln out of the original 108 million shares under the agreement of July 2014. the S-1 clearly states that the "63 million shares" of this prospectus represents the remaining 27 million plus the 36 million or being added to the agreement…
“Although the Purchase Agreement provides that we may sell up to $40,000,000 of our common stock to Lincoln Park, only 63,000,000 shares of our common stock are being offered under this prospectus, which represents (i) 872,388 shares registered, remaining unissued under the Prior Registration Statement which are issuable to Lincoln Park as a commitment fee, (ii) 26,258,385 shares registered and remaining unsold under the Prior Registration Statement and issued or issuable to Lincoln Park under the Purchase Agreement and (iii) an additional 35,869,227 shares which may be issued to Lincoln Park in the future under the Purchase Agreement.“
with cash on hand and the $7.5 milestone when SequestOx is approved, Hakim probably has enough to get ELI-201 and 202 submitted AND build inventory for the launch of SequestOx but he may want access to additional cash in case it is needed
keep in mind, approval is around the corner and we don't know if Puracap is really going to honor the Elite/Epic agreement(s), so Hakim might be increasing the shares that can be sold to Lincoln as an alternative to Puracap doing distribution. notice what he said on the conference call...
"If we are to get approval without an AdCom meeting, hallelujah! We will start making large quantities. And we can also decide whether we want to go at it our self. We’ll have to raise some money; we have some money but we’ll have to raise some money as well to do that. So, it’s getting close; it’s getting tough, but I’m not getting nervous about it, because frankly, the day they give us approval, we can start making the large quantities and things will start to come together."
on 7/8/14, Elite entering into an agreement with Lincoln Park whereby Elite could require LP to buy shares
a total of 108 million shares were made available for that purpose
two years later, only 27 million shares remain available under that agreement
the purpose of the S-1 prospectus is to increase the shares that can be sold to LP by 35 million -- hence the 63 million share figure which is the 27 million remaining plus the 35 million being added
seems FDA offered a label but company said abuse resistant or nothing, and they got nothing
nobody, but nobody, has Elite's two-bead technology, not pfizer, not teva, not anybody
Elite ALSO has one-bead technology that is essentially the same as what pfizer is doing and, though Hakim is disappointed they got there first he also appreciates that it would have cost an arm and a leg to go first and Elite can now benefit by what pfizer went through and get Elite's version through FDA cheaper and quicker -- though it obviously will not be worth as much
but do NOT confuse immediate release SequestOx with all the extended release entries out there. SequestOx will be the first abuse resistant immediate release oxy, the first in the largest segment by far of the oxy market, and it will have established itself well before any competition shows up, yes, there are giants playing in the field of abuse resistance but when it comes to immediate release they are still in the parking lot while Elite is closing out the ninth inning with a 10 run lead
explain how it dropped from $99 million at the end of March 2014 to just $12 million end of March 2016
and then stop saying Elite has a lot of debt and negatives on its balance sheet
there's nothing complicated about the share structure. just read the 10-k and ask whatever questions arise but, if you actually read it, i doubt you will have any problem understanding how many shares are outstanding and authorized
as for the number of shares -- unimportant! the only thing that matters is market cap and, on that score, Elite's cap is much, much lower than similar companies, and most of those companies have no revenues whatever let alone revenues that are paying for R&D
and the balance sheet is beautiful. nothing like when Hakim took over. it is now rock solid -- Elite is actually funding itself, including R&D, for the first time in its history. don't worry about the debt because it is almost entirely contained in the warrants and will disappear whenever they are exercised or bought back
finally, why are you still talking 1-2 million? have you read the latest report? do you not realize Elite had $5.2 million in revs the last quarter? that's for just one quarter, monkey, not a year, just one quarter. and we you start applying triple digit growth to that kind of number and then start factoring in some SequestOx sales in 2017, well...you got yourself quadruple digit revenue growth!
what are you talking about? Elite has virtually NO debt. that entry on the balance sheet includes the value of warrants that have been issued. when the stock goes up, long term debt and stockholders' deficit also go up. and when the stock goes down, so does the debt and deficit
and if you don't want to accept that reality, then i will use your misinterpretation and ask you, isn't it terrific that Elite had $99 million in long term debt as of 3/31/14 and in just two years has paid in down to only $12 million?
i mean, wow, according to your shrewd reading of financial statements, Elite has paid off $87 million in debt in just two years! thanks, monkeybreath, for bringing that to our attention
with generic revenues growing so fast, that outcome might become the norm
fundamental problem is that the market cap reflects expectations that they have mass market products when, in fact, there are much cheaper alternatives available for most of that market
it's not enough to have a good product, it also has to be a necessary product, and that is simply not the case with cers -- and that is why the current price at 18 times sales is not sustainable
that includes the money from barda which also requires cers to spend $15 million
just look at the estimates for the rest of 2016 and through 2017
there are no profits in sight, and current market cap(18 times sales and seven times book value) has already more than factored in all the agreements and catalysts and pending approvals
up 300 percent since then and expect there is much, much, much more to be made
extremely high expectations are reflected in current lofty market cap
no other justification for the stock price being super high at this point
does not seem to be room to go up from here, only down
well, it isn't an exciting, ground-breaking, breast or liver cancer treatment. in fact, anything involving opioids is viewed rather darkly these days, sort of a necessary evil until some non-addictive approach to break-through pain relief becomes available
and, keep in mind that even the FDA said they had never seen anything like Elite's approach, so there must be a lot of experienced, won't-be-fooled-again skeptics out there, especially after seeing recent failures AND seeing lousy sales of other abuse resistant drugs. of course, those drugs had/have serious shortcomings but most investors tend to paint whole sectors with a broad brush, and Elite is in a very out of favor sector
but possibly the biggest factors are these:
- it's a bulletin board penny stock
- there were approximately 136 shareholders as of June 7th
in other words, Elite is very much under the radar and might well remain so until perhaps the second qtr of Sequest sales, that is why, if you believe in Hakim, this is an excellent time to buy as much ELTP as you can, most of which should be held at least until the next abuse resistant drug is approved and it is evident to all that Elite's entire pipeline is on its way to approval
from the 10-k...
"Elite will receive a license fee computed as a percentage (50%) of net sales of the Products a defined in the Agreement and is entitled to multi million dollar minimum annual license fees. Elite will manufacture the product for sale by Epic on a cost plus basis"
did much, much better than even i expected
and, the balance sheet that was in tatters when Hakim arrived has become a thing of beauty